Adicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Rhea-AI Summary

Adicet Bio, Inc. (NASDAQ: ACET) announced updated safety and efficacy data from the Phase 1 study of ADI-001 for treating relapsed or refractory B-cell Non-Hodgkin’s Lymphoma. This data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7, 2022. The oral presentation, titled 'A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta T cells in adults with B-cell malignancies', is scheduled for June 6, 2022, at 8:00 AM CDT, featuring Sattva Neelapu, MD, from MD Anderson Cancer Center.

Positive

• Presentation of updated safety and efficacy data from the Phase 1 study of ADI-001.
• Opportunity to showcase results at a major event like ASCO Annual Meeting.

Negative

• None.

MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that updated safety and efficacy data from the Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin’s Lymphoma (NHL) will be delivered as an oral presentation at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and online June 3-7, 2022.

Details of the oral presentation are as follows:
Abstract Number: 7509
Abstract Title: A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) t cells in adults with B-cell malignancies
Presenting Author: Sattva Neelapu, MD, MD Anderson Cancer Center
Session Type/Title: Clinical Science Symposium/ Beating Bad Blood: The Power of Immunotherapy in Hematologic Malignancies
Date: June 6, 2022
Time: 8:00 AM-9:30 AM CDT

The abstract will be available on Thursday, May 26 at 5:00 PM EDT on ASCO.org.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005290/en/

Adicet Bio., Inc.

Investor and Media Contacts

Anne Bowdidge

abowdidge@adicetbio.com

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

janhavi.mohite@sternir.com

Source: Adicet Bio, Inc.

FAQ

What is the focus of Adicet Bio's Phase 1 study of ADI-001?

The Phase 1 study focuses on the safety and efficacy of ADI-001, an anti-CD20 CAR-engineered allogeneic gamma delta T cell therapy for relapsed or refractory B-cell Non-Hodgkin’s Lymphoma.

When will the updated data for ADI-001 be presented?

The updated data will be presented on June 6, 2022, at the ASCO Annual Meeting.

Who is presenting the ADI-001 study results?

The study results will be presented by Sattva Neelapu, MD, from MD Anderson Cancer Center.

What is the significance of the ASCO Annual Meeting for Adicet Bio?

The ASCO Annual Meeting provides a platform for Adicet Bio to share important clinical data with the oncology community, potentially impacting investor perception and interest.